Assessment of the Duration of Protection in
Campylobacter jejuni
Experimental Infection in Humans
-
Published:2010-04
Issue:4
Volume:78
Page:1750-1759
-
ISSN:0019-9567
-
Container-title:Infection and Immunity
-
language:en
-
Short-container-title:Infect Immun
Author:
Tribble David R.1, Baqar Shahida1, Scott Daniel A.1, Oplinger Michael L.2, Trespalacios Fernando2, Rollins David1, Walker Richard I.3, Clements John D.4, Walz Steven1, Gibbs Paul2, Burg Edward F.1, Moran Anthony P.5, Applebee Lisa1, Bourgeois A. Louis1
Affiliation:
1. Naval Medical Research Center, Silver Spring, Maryland 2. U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 3. Antex Biologics, Gaithersburg, Maryland 4. Tulane University School of Medicine, New Orleans, Louisiana 5. National University of Ireland, Galway, Ireland
Abstract
ABSTRACT
A human
Campylobacter jejuni
infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain,
C. jejuni
81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and duration of protection. Healthy
Campylobacter
-seronegative adults received
C. jejuni
strain 81-176 via oral inoculation of 10
5
, 10
7
, or 10
9
CFU (5 adults/dose), which was followed by clinical and immunological monitoring. Based on dose range clinical outcomes, the 10
9
-CFU dose (
n
= 31) was used to assess homologous protection at 28 to 49 days (short-term veterans [STV];
n
= 8) or 1 year (long-term veterans [LTV];
n
= 7) after primary infection. An illness dose effect was observed for naïve subjects (with lower doses, 40 to 60% of the subjects were ill; with the 10
9
-CFU dose, 92% of the subjects were ill) along with complete protection for the STV group and attenuated illness for the LTV group (57%). Partial resistance to colonization was seen in STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment.
Campylobacter
antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to
C. jejuni
. This study revealed a
C. jejuni
dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Immunology,Microbiology,Parasitology
Reference55 articles.
1. Ailes, E., L. Demma, S. Hurd, J. Hatch, T. F. Jones, D. Vugia, A. Cronquist, M. Tobin-D'Angelo, K. Larson, E. Laine, K. Edge, S. Zansky, and E. Scallan. 2008. Continued decline in the incidence of Campylobacter infections, FoodNet 1996-2006. Foodborne Pathog. Dis.5:329-337. 2. Altekruse, S. F., D. L. Swerdlow, and N. J. Stern. 1998. Microbial food borne pathogens. Campylobacter jejuni. Vet. Clin. N. Am.14:31-40. 3. Immunogenicity and Protective Efficacy of Recombinant
Campylobacter jejuni
Flagellum-Secreted Proteins in Mice 4. Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation 5. Baqar, S., B. Rice, L. Lee, A. L. Bourgeois, A. N. El Din, D. R. Tribble, G. P. Heresi, A. S. Mourad, and J. R. Murphy. 2001. Campylobacter jejuni enteritis. Clin. Infect. Dis.33:901-905.
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|